Il-28b predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations

Journal of General Virology

Volumn 92, Issue 5, 2011, Pages 1071-1081

  Ochi, Hidenori ^a,b   Maekawa, Toshiro ^a   Abe, Hiromi ^a,b   Hayashida, Yasufumi ^b   Nakano, Rikita ^c   Imamura, Michio ^b   Hiraga, Nobuhiko ^b   Kawakami, Yoshiiku ^d   Aimitsu, Shiomi ^e   Kao, Jia Horng ^f   Tsunoda, Michiaki Kubo ^a   Tsunoda, Tatsuhiko ^a   Kumada, Hiromitsu ^g   Nakamura, Yusuke ^h   Hayes, Nelson C ^b   Chayama, Kazuaki ^a,b  

^a RIKEN   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^d HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^e ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g TORANOMON HOSPITAL   (Japan)

^h THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ALLELE; ARTICLE; ASIAN; CONTROLLED STUDY; FIBROSIS; GENE MAPPING; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 79955591125     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.029124-0     Document Type: Article

References (41)

1. Akuta, N., Suzuki, F., Kawamura, Y., Yatsuji, H., Sezaki, H., Suzuki, Y., Hosaka, T., Kobayashi, M., Kobayashi, M. & other authors (2007). Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46, 403-410.
2. Barrera, J. M., Bruguera, M., Ercilla, M. G., Gil, C., Celis, R., Gil, M. P., del Valle Onorato, M., Rodes, J. & Ordinas, A. (1995). Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 21, 639-644.
3. Bressler, B. L., Guindi, M., Tomlinson, G. & Heathcote, J. (2003). High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38, 639-644.
4. Casiraghi, M. A., De Paschale, M., Romano, L., Biffi, R., Assi, A., Binelli, G. & Zanetti, A. R. (2004). Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 39, 90-96.
5. Charlton, M. R., Thompson, A., Veldt, B. J., Watt, K., Tillmann, H., Poterucha, J. J., Heimbach, J. K., Goldstein, D. & McHutchison, J. (2011). Interleukin-28B polymorphisms are associated with histolo-gical recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53, 317-324.
6. Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L. L., Coltescu, C., Heathcote, J., Edwards, A. M. & McGilvray, I. D. (2005). Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444.
7. Conjeevaram, H. S., Fried, M. W., Jeffers, L. J., Terrault, N. A., Wiley-Lucas, T. E., Afdhal, N., Brown, R. S., Belle, S. H., Hoofnagle, J. H. & other authors (2006). Peginterferon and ribavirin treatment in African American and caucasian American patients with hepatitis C genotype 1. Gastroenterology 131, 470-477.
8. Desmet, V. J., Gerber, M., Hoofnagle, J. H., Manns, M. & Scheuer, P. J. (1994). Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19, 1513-1520.
9. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F. & Sato, C. (1996). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334, 77-82.
10. Feld, J. J., Nanda, S., Huang, Y., Chen, W., Cam, M., Pusek, S. N., Schweigler, L. M., Theodore, D., Zacks, S. L. & other authors (2007). Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46, 1548-1563.
11. Fukuhara, T., Taketomi, A., Motomura, T., Okano, S., Ninomiya, A., Abe, T., Uchiyama, H., Soejima, Y., Shirabe, K. & other authors (2010). Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139, 1577-1585, 1585, e1-e3.
12. Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A. & other authors (2002). The structure of haplotype blocks in the human genome. Science 296, 2225-2229.
13. Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H. & other authors (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401.
14. Hadziyannis, S. J., Sette, H., Jr, Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr, Bernstein, D. & other authors (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140, 346-355.
15. Hijikata, M., Ohta, Y. & Mishiro, S. (2000). Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 43, 124-127.
16. Honda, M., Sakai, A., Yamashita, T., Nakamoto, Y., Mizukoshi, E., Sakai, Y., Yamashita, T., Nakamura, M., Shirasaki, T. & other authors (2010). Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139, 499-509.
17. KennyWalsh, E. &Irish Hepatology Research Group (1999). Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 340, 1228-1233.
18. Knapp, S., Yee, L. J., Frodsham, A. J., Hennig, B. J., Hellier, S., Zhang, L., Wright, M., Chiaramonte, M., Graves, M. & other authors (2003). Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 4, 411-419.
19. Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H. & Donnelly, R. P. (2003). IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4, 69-77.
20. Maher, S. G., Sheikh, F., Scarzello, A. J., Romero-Weaver, A. L., Baker, D. P., Donnelly, R. P. & Gamero, A. M. (2008). IFNa and IFNl differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7, 1109-1115.
21. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. & Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
22. Marcello, T., Grakoui, A., Barba-Spaeth, G., Machlin, E. S., Kotenko, S. V., MacDonald, M. R. & Rice, C. M. (2006). Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887-1898.
23. Matsuyama, N., Mishiro, S., Sugimoto, M., Furuichi, Y., Hashimoto, M., Hijikata, M. & Ohta, Y. (2003). The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 25, 221-225.
24. Naito, M., Matsui, A., Inao, M., Nagoshi, S., Nagano, M., Ito, N., Egashira, T., Hashimoto, M., Mishiro, S. & other authors (2005). SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 40, 381-388.
25. Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H. & Nakamura, Y. (2001). A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46, 471-477.
26. Pagliaccetti, N. E., Eduardo, R., Kleinstein, S. H., Mu, X. J., Bandi, P. & Robek, M. D. (2008). Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 283, 30079-30089.
27. Robek, M. D., Boyd, B. S. & Chisari, F. V. (2005). Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79, 3851-3854.
28. Romero-Gómez, M., Del Marviloria, M., Andrade, R. J., Salmero n, J., Diago, M., FernandezRodriguez, C. M., Corpas, R., Cruz, M., Grande, L. & other authors (2005). Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128, 636-641.
29. Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H., Christen, V., Terracciano, L., Filipowicz, W. & Heim, M. H. (2008). Interferonsignaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105, 7034-7039.
30. Sarrazin, C., Susser, S., Doehring, A., Lange, C. M., Mü ller, T., Schlecker, C., Herrmann, E., Lö tsch, J. & Berg, T. (2010). Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol.
31. Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C. & other authors (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4, 63-68.
32. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J. & other authors (2009). IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 41, 1100-1104.
33. Suzuki, A., Yamada, R., Chang, X., Tokuhiro, S., Sawada, T., Suzuki, M., Nagasaki, M., Nakayama-Hamada, M., Kawaida, R. & other authors (2003). Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34, 395-402.
34. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K. & other authors (2009). Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41, 1105-1109.
35. Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O'Huigin, C., Kidd, J., Kidd, K., Khakoo, S. I. & other authors (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801.
36. Tsubota, A., Chayama, K., Ikeda, K., Yasuji, A., Koida, I., Saitoh, S., Hashimoto, M., Iwasaki, S., Kobayashi, M. & Hiromitsu, K. (1994). Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 19, 1088-1094.
37. Tsukada, H., Ochi, H., Maekawa, T., Abe, H., Fujimoto, Y., Tsuge, M., Takahashi, H., Kumada, H., Kamatani, N. & other authors (2009). A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 136, 1796-1805, e6.
38. Urban, T. J., Thompson, A. J., Bradrick, S. S., Fellay, J., Schuppan, D., Cronin, K. D., Hong, L., McKenzie, A., Patel, K. & other authors (2010). IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888-1896.
39. Welzel, T. M., Morgan, T. R., Bonkovsky, H. L., Naishadham, D., Pfeiffer, R. M., Wright, E. C., Hutchinson, A. A., Crenshaw, A. T., Bashirova, A. & other authors (2009). Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49, 1847-1858.
40. Yamaguchi-Kabata, Y., Nakazono, K., Takahashi, A., Saito, S., Hosono, N., Kubo, M., Nakamura, Y. & Kamatani, N. (2008). Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet 83, 445-456.
41. Zhu, H., Butera, M., Nelson, D. R. & Liu, C. (2005). Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2, 80.